|

TQB2450 +Androtinib Placebo+Docetaxel Clinical Trials

1 actively recruiting trial

Also known as: TQB2450/Anlotinib Placebo/Docetaxel

Pipeline

Phase 2: 1

Top Sponsors

  • Tianjin Medical University Cancer Institute and Hospital1

Indications

  • Lung Cancer1
  • Non Small Cell Lung Cancer1
  • Cancer1

Other1 trial

Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.